Investigational drug · Phase 3
CDK4
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced ER+/HER2- Breast Cancer, Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
483
Any phase or sponsor naming "CDK4"
First trial start
2025
Apr 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CDK4", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced ER+/HER2- Breast Cancer
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CDK4" as an intervention, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03701334 · 5,101 participants · Start Dec 7, 2018 · Primary completion May 29, 2030
Drug: Ribociclib · For: Early Breast Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Jonesboro, Arkansas · 387 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05141240 · 4,650 participants · Start Apr 15, 2020 · Primary completion Jun 15, 2020
Drug: Ribiciclib; Palbociclib and 1 more · For: Metastatic Breast Cancer
Sites: East Hanover, New Jersey
Novartis PharmaceuticalsNovartis (NVS)
NCT05153135 · 4,320 participants · Start May 8, 2020 · Primary completion Jul 31, 2020
Drug: Ribociclib; Palbociclib and 1 more · For: Metastatic Breast Cancer
Sites: East Hanover, New Jersey
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
NCT06805812 · 3,500 participants (planned) · Start May 1, 2023 · Primary completion Dec 31, 2030
Drug: Palbociclib; Ribociclib and 1 more · For: Breast Adenocarcinoma; Breast Cancer Stage IV; Breast Cancer, Metastatic and 38 more
Sites: Aviano, Italy; Brescia, Italy; Catania, Italy · 24 sites in all
- Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02941926 · 3,246 participants · Start Nov 30, 2016 · Primary completion Nov 8, 2019
Drug: Ribociclib; Letrozole and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Phoenix, Arizona · 495 sites in all
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07153757 · 2,934 participants (planned) · Start Sep 1, 2025 · Primary completion Sep 1, 2033
Drug: Endocrine Therapy of Physician's Choice · For: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Sites: Shanghai, China
PfizerPfizer (PFE)
NCT05361655 · 2,888 participants · Start Sep 1, 2021 · Primary completion Sep 1, 2021
Drug: Palbociclib + an aromatase inhibitor; Aromatase inhibitor · For: Metastatic Breast Cancer
Sites: New York, New York
Novartis PharmaceuticalsNovartis (NVS)
NCT06930859 · 2,766 participants (planned) · Start Dec 3, 2025 · Primary completion Dec 31, 2032
Drug: Ribociclib; Letrozole and 1 more · For: Breast Cancer
Sites: Sochi, Russia; Kaluga, Russia; Pskov, Russia · 49 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- CDK4/6 inhibition suppresses mTOR activity and growth in lymphangioleiomyomatosis (LAM).
Kundu N, Fard SS, Di Martino JS, et al. · Biochim Biophys Acta Mol Basis Dis 2027
- Integrative Systems Biology Prioritizes BCL2, ALK, and CDK4 as Therapeutic Candidates in Neuroblastoma through Multi-Centrality Network Analysis, Cross-Database Validation, Independent Docking Validation, and Confidence-Threshold Sensitivity Analysis.
Zabihi A · Comput Biol Chem 2027
- The peripheral immune landscape of human breast cancer.
García-Torralba E, Buqué A, Galluzzi L · Oncoimmunology 2026
- Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.
Tan Y, Ye Y, Zhao W, et al. · Cancer Biol Ther 2026
- CDK4/6 Inhibitors and Endocrine Therapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Real-World Cohort.
Marin-Trigueros D, Landaverde DU · World J Oncol 2026
- Gene amplification during differentiation of mesenchymal stem cells towards chondrocytes.
Schwarz PE, Cucchiarini M, Rishik S, et al. · Exp Ther Med 2026
Also in development for Advanced ER+/HER2- Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.